D20054;LITT for Spine Tumors
NCT06548061
Recruiting
The objective of this clinical study is to evaluate the efficacy and safety of spinal laser interstitial therapy in the treatment of metastatic spinal tumors. The investigators hypothesize that rates of local tumor control are comparable between conventional open surgical techniques and spinal laser interstitial therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Dartmouth Health, Lebanon, New Hampshire
Conditions: Spinal Metastases
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450
Recruiting
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/01/2025
Locations: USC San Diego Health, La Jolla, California +10 locations
Conditions: Advanced Solid Tumors Cancer, MSI-H Cancer
Register for Updates
NO During CPB in Neonates to Reduce Risk of AKI
NCT04216927
Recruiting
Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent vasodilator. The investigators hypothesize tha... Read More
Gender:
ALL
Ages:
Between 1 day and 31 days
Trial Updated:
04/01/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: AKI, CHD - Congenital Heart Disease, Surgery
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +944 locations
Conditions: Stage III Colon Cancer
Register for Updates
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
NCT05582187
Recruiting
The primary purpose of this open-label study is to characterize the plasma pharmacokinetics (PK) of manogepix (active moiety of fosmanogepix) in participants with varying degrees of hepatic function following administration of a single oral dose of fosmanogepix. All participants will receive 1 dose of fosmanogepix by mouth before breakfast on the first day at the study clinic. Serial blood samples will be collected to understand how fosmanogepix is changed and eliminated from the body. Particip... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2025
Locations: Inland Empire Liver Foundation, Rialto, California +1 locations
Conditions: Hepatic Impairment
Register for Updates
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541
Recruiting
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of California, Davis Comprehensive Cancer Center, Sacramento, California +16 locations
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
Longitudinal Investigation of Sleep, Memory, and Brain Development Across the Nap Transition
NCT06351098
Recruiting
To examine the relations between sleep (nap transitions, sleep physiology), memory, and brain development longitudinally, the researchers will assess n=180 children (in order to acquire n=152 usable data sets) who are 36-54 months of age and habitual nappers at enrollment. In each wave, the researchers will assess memory, memory change over a nap and equivalent waking interval, sleep physiology of the nap, and brain structure and function (using Magnetic Resonance Imagining or MRI). Additionally... Read More
Gender:
ALL
Ages:
Between 36 months and 60 months
Trial Updated:
04/01/2025
Locations: University of Maryland, College Park, Maryland +1 locations
Conditions: Memory
Register for Updates
Pilot of an Online Sexual Health Program
NCT06564025
Recruiting
This study proposes to pilot an online intervention to support father-teen health-promoting talk about sex and relationships using Social Cognitive Theory, and to evaluate this intervention's acceptability, feasibility, and preliminary efficacy, using an Intervention Mapping approach. This study involves conducting a pilot intervention with 50 pairs of fathers and their high-school aged teens. Feasibility and acceptability will be assessed through program data such as participants' pilot enrollm... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
04/01/2025
Locations: Wellesley College, Wellesley, Massachusetts
Conditions: Program, Communication
Register for Updates
CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases
NCT06907953
Recruiting
The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Primary Ciliary disease (PCD). This study aims to use multimodal digital health tools to enable patients to self-monitor their symptoms in passive and active ways.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
04/01/2025
Locations: 4YouandMe, New York, New York
Conditions: Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
Register for Updates
Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia
NCT04267003
Recruiting
People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these cognitive problems. The current study investigates whether or not delivering a very small electrical current to people's foreheads (called, transcranial direct current stimulation; (tDCS)) might improve functioning in the front part of the brain and red... Read More
Gender:
ALL
Ages:
Between 18 years and 47 years
Trial Updated:
04/01/2025
Locations: Imaging Research Center, Sacramento, California
Conditions: Schizophrenia
Register for Updates
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126
Recruiting
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Register for Updates
Tocilizumab for Acute Chest Syndrome
NCT05640271
Recruiting
The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigator... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Sickle Cell Disease, Acute Chest Syndrome
Register for Updates